Adult Patients Affected by Cystic Fibrosis in Therapy with Cystic Fibrosis Transmembrane Regulator Modulators and Lung Transplant: Renal Function, Metabolic and Nutritional Status
Table 2
Patients’ characteristics at T1 (after 3 years).
T1
Group 0 N = 29
Group 1 N = 19
Group 2 N = 21
value
Creatinine (mg/dL)
0.78 ± 0.4
0.76 ± 0.16
1.16 ± 0.34
eGFR (ml/min)
107.66 ± 25.01
113.0 ± 22.38
69.38 ± 20.93
Serum nitrogen (mg/dL)
5.21 ± 1.49
5.52 ± 1.21
9.64 ± 3.34
Serum uric acid (mmol/L)
0.32 ± 0.06
0.34 ± 0.07
0.43 ± 0.10
Serum sodium (mEq/L)
141.14 ± 3.21
140.53 ± 1.93
143.62 ± 2.65
Serum potassium (mEq/L)
4.58 ± 0.32
4.46 ± 0.27
3.94 ± 0.52
Total protein (g/dL)
78.52 ± 6.21
75.58 ± 5.13
67.29 ± 4.17
Serum albumin (g/dL)
44.55 ± 4.44
46.26 ± 4.62
42.74 ± 3.47
Serum fibrinogen (g/L)
3.52 ± 0.84
3.17 ± 0.78
2.93 ± 0.75
Serum transferrin (g/L)
2.53 ± 0.36
3.16 ± 0.64
2.52 ± 0.61
White blood cells, ×10³/μL
8.58 ± 2.66
6.50 ± 1.58
7.85 ± 1.76
HbA1c (%)
5.74 ± 0.73
5.98 ± 0.85
6.54 ± 1.19
CRP (μg/L)
9552.0 ± 20573.49
1966.67 ± 2119.75
6265.79 ± 9016.59
NLR
2.89 ± 4.34
2.44 ± 0.85
2.70 ± 1.43
Neutrophils, ×10³ (μL)
6197.8 ± 1080.0
5070.52 ± 1920.0
5897.6 ± 1900.0
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, A1c haemoglobin; N, number of patients; NLR, neutrophil-to-lymphocyte ratio. Data are shown as mean ± standard deviation or number (%). Group 0: CF patients on conservative therapy (controls); group 1: CF patients with CFTR modulator therapy; group 2: LT patients.
